New Upstream Dual Listing: Quantum BioPharma
Quantum BioPharma, Ltd. is now available on Upstream under the ticker symbol ‘QNTM’.
The dual listing on Upstream is designed to provide Quantum BioPharma the opportunity to access a global investor base outside the U.S., unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in the company.
Traders on Upstream’s smart contract-powered platform will experience real-time trading and settlement, and a transparent orderbook which does not permit common market manipulations. Trading will commence when an existing shareholder places an offer for sale on Upstream establishing the first trade. Note, U.S. persons may not deposit, buy or sell securities on Upstream.
Details on the Quantum BioPharma listing and deposit and trading instructions can be found at https://upstream.exchange/quantumbiopharma.
Get to know Quantum BioPharma:
For the Upstream community who may not know you yet, please give a short intro on who your company is?
QuantumBioPharma Ltd. (formerly, FSD Pharma Inc.) (“Quantum” or the “Company”) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (“Lucid-MS”). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum is also focused on the research and development of a treatment for alcohol misuse for application in hospitals and other medical practices. Quantum maintains a portfolio of strategic investments through its wholly-owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential property.
What’s one or two of your biggest initiatives this year as a company?
Quantum is set to announce trial results on alcohol misuse using its product, Unbuzzd, in the coming quarter. Additionally, the ongoing trial of Lucid-MS aims to deliver a groundbreaking human efficacy signal for the reversal of mobility loss for the very first time in a patient with multiple sclerosis.
What’s a recent trend in your industry that you believe sets up your company for success?
Unbuzzd is uniquely positioned to leverage influencers to ramp up sales due to the need for education about its benefits. A product like Unbuzzd, backed by proven science and efficacy, does not currently exist in the market, making it a groundbreaking innovation. Additionally, the potential market for Unbuzzd, which helps individuals sober up from alcohol faster, is vast and largely untapped, offering significant growth opportunities.
Why should shareholders be excited about the dual listing with Upstream?
After listing on Upstream, investors from around the world, including various territories, will have the opportunity to buy our stock, providing the company with greater exposure to potential investors and shareholders. Additionally, one significant advantage is that investors and potential shareholders will be able to transact using cryptocurrencies for buying and selling, offering greater flexibility and accessibility.
Where can shareholders learn more about your dual listing and how to participate in digital rewards?
Company Website: https://www.quantumbiopharma.com/investors
Upstream profile page: https://upstream.exchange/quantumbiopharma
Disclaimers:
U.S. persons may not deposit, buy or sell securities on Upstream.
This communication does not constitute an offer to sell securities or the solicitation of an offer to buy securities in any jurisdiction where such offer or solicitation is not permitted.
Upstream is a MERJ Exchange market. MERJ Exchange is a licensed Securities Exchange, an affiliate of the World Federation of Exchanges, a National Numbering Agency, and a member of ANNA. MERJ is regulated in the Seychelles by the Financial Services Authority, https://fsaseychelles.sc/, an associate member of the International Association of Securities Commissions (IOSCO). MERJ supports global issuers of traditional and digital securities through the entire asset life cycle from issuance to trading, clearing, settlement, and registry. It operates a fair and transparent marketplace in line with international best practices and principles of operations of financial markets. Upstream does not endorse or recommend any public or private securities bought or sold on its app. Upstream does not offer investment advice or recommendations of any kind. All services offered by Upstream are intended for self-directed clients who make their own investment decisions without aid or assistance from Upstream. All customers are subject to the rules and regulations of their jurisdiction. By accessing the site or app, you agree to be bound by its terms of use and privacy policy. Company and security listings on Upstream are only suitable for investors who are familiar with and willing to accept the high risk associated with speculative investments, often in early and development-stage companies. U.S. persons may not deposit, buy, or sell securities on Upstream. There can be no assurance the valuation of any particular company’s securities is accurate or in agreement with the market or industry comparative valuations. Investors must be able to afford market volatility and afford the loss of their investment. Companies listed on Upstream are subject to significant ongoing corporate obligations including, but not limited to disclosure, filings, and notification requirements, as well as compliance with applicable quantitative and qualitative listing standards.
Forward-Looking Statements
This blog contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus and other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.